Pharma Aids Limited (DSE: PHARMAID)
Bangladesh
· Delayed Price · Currency is BDT
623.20
+12.20 (2.00%)
At close: Nov 14, 2024
Pharma Aids Income Statement
Financials in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | 2019 - 2015 |
Revenue | 421.23 | 421.23 | 308.49 | 323.05 | 280.29 | 269.57 | Upgrade
|
Revenue Growth (YoY) | 36.54% | 36.54% | -4.51% | 15.25% | 3.98% | 8.24% | Upgrade
|
Cost of Revenue | 291.1 | 291.1 | 257.2 | 219.58 | 174.95 | 163.13 | Upgrade
|
Gross Profit | 130.13 | 130.13 | 51.29 | 103.47 | 105.34 | 106.44 | Upgrade
|
Selling, General & Admin | 45.85 | 45.85 | 37.32 | 45.63 | 38.17 | 33.55 | Upgrade
|
Other Operating Expenses | - | - | 2.21 | 1.94 | 0.07 | 0.12 | Upgrade
|
Operating Expenses | 45.85 | 45.85 | 40.63 | 49.45 | 39.02 | 34.61 | Upgrade
|
Operating Income | 84.28 | 84.28 | 10.66 | 54.02 | 66.33 | 71.84 | Upgrade
|
Interest Expense | -0.38 | -0.38 | -0.24 | -0.38 | -0.9 | -0.89 | Upgrade
|
Other Non Operating Income (Expenses) | 0.66 | 0.66 | -0.13 | -0.09 | -0.07 | -0.14 | Upgrade
|
EBT Excluding Unusual Items | 84.56 | 84.56 | 10.3 | 53.54 | 65.35 | 70.81 | Upgrade
|
Gain (Loss) on Sale of Assets | - | - | - | - | - | -0.84 | Upgrade
|
Pretax Income | 84.56 | 84.56 | 10.3 | 53.54 | 65.35 | 69.97 | Upgrade
|
Income Tax Expense | 23.38 | 23.38 | 16.68 | 18.78 | 15.1 | 17.49 | Upgrade
|
Net Income | 61.19 | 61.19 | -6.38 | 34.76 | 50.26 | 52.47 | Upgrade
|
Net Income to Common | 61.19 | 61.19 | -6.38 | 34.76 | 50.26 | 52.47 | Upgrade
|
Net Income Growth | - | - | - | -30.83% | -4.22% | 8.62% | Upgrade
|
Shares Outstanding (Basic) | 3 | 3 | 3 | 3 | 3 | 3 | Upgrade
|
Shares Outstanding (Diluted) | 3 | 3 | 3 | 3 | 3 | 3 | Upgrade
|
Shares Change (YoY) | 0.21% | 0.01% | - | - | - | - | Upgrade
|
EPS (Basic) | 19.61 | 19.61 | -2.05 | 11.14 | 16.11 | 16.82 | Upgrade
|
EPS (Diluted) | 19.61 | 19.61 | -2.05 | 11.14 | 16.11 | 16.82 | Upgrade
|
EPS Growth | - | - | - | -30.83% | -4.22% | 8.62% | Upgrade
|
Free Cash Flow | 22.6 | 22.6 | 5.06 | 29.15 | 21.12 | 35.69 | Upgrade
|
Free Cash Flow Per Share | 7.24 | 7.24 | 1.62 | 9.34 | 6.77 | 11.44 | Upgrade
|
Dividend Per Share | - | - | 1.000 | 5.000 | 5.000 | 5.000 | Upgrade
|
Dividend Growth | - | - | -80.00% | 0% | 0% | 0% | Upgrade
|
Gross Margin | 30.89% | 30.89% | 16.63% | 32.03% | 37.58% | 39.49% | Upgrade
|
Operating Margin | 20.01% | 20.01% | 3.46% | 16.72% | 23.66% | 26.65% | Upgrade
|
Profit Margin | 14.53% | 14.53% | -2.07% | 10.76% | 17.93% | 19.47% | Upgrade
|
Free Cash Flow Margin | 5.37% | 5.37% | 1.64% | 9.02% | 7.54% | 13.24% | Upgrade
|
EBITDA | 91.2 | 91.2 | 18.29 | 61.84 | 74.58 | 80.41 | Upgrade
|
EBITDA Margin | 21.65% | 21.65% | 5.93% | 19.14% | 26.61% | 29.83% | Upgrade
|
D&A For EBITDA | 6.92 | 6.92 | 7.62 | 7.82 | 8.25 | 8.57 | Upgrade
|
EBIT | 84.28 | 84.28 | 10.66 | 54.02 | 66.33 | 71.84 | Upgrade
|
EBIT Margin | 20.01% | 20.01% | 3.46% | 16.72% | 23.66% | 26.65% | Upgrade
|
Effective Tax Rate | 27.65% | 27.65% | 161.99% | 35.07% | 23.10% | 25.00% | Upgrade
|
Advertising Expenses | - | - | 0.89 | 0.97 | 0.96 | 0.8 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.